Medical technology company developing robotic systems for Aquablation therapy to treat benign prostatic hyperplasia.
Profile & Fundamentals
PROCEPT BioRobotics: Company identity, ownership, reported financial performance, balance sheets, and corporate actions.
Profile & Fundamentals
PROCEPT BioRobotics Profile & Fundamentals
Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.
Explore this pageJump to a Profile & Fundamentals section
Explore this research
Profile & Fundamentals contents
Jump directly to any section
Company and Market Context
Company Profile & Ownership
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
Company profile record
Procept Biorobotics Corp
Common Stock · Health Care · Health Care Equipment
Company
- Company / asset
- Procept Biorobotics Corp
- Security type
- Common Stock
- Sector
- Health Care
- Industry
- Health Care Equipment
- HQ
- 🇺🇸 United States
- Head office
- 150 Baytech Drive, San Jose, CA, United States, 95134
Leadership & scale
- Chief executive
- Mr. Larry L. Wood
- CEO year born
- 1966
- Full-time employees
- 888
- Fiscal year end
- December
- IPO date
- 2021-09-15
Fundamentals snapshot
- Market Cap
- USD 989.5M
- P/E
- --
- Revenue (Q2 26)
- USD 94.5M
- Profit (Q2 26)
- USD -26.9M
- Dividend Yield
- --
- Revenue (FY 25)
- USD 308.1M
- Shares in public float
- 55.8M
- Insider ownership
- 3.48%
Reporting & identifiers
- Symbol
- PRCT.NASDAQ
- Listing
- 🇺🇸 United States | Dividend Tax: 30%
- Ticker Currency
- USD
- Income Statement Currency
- USD
- Balance Sheet Currency
- USD
- Cash Flow Currency
- USD
- EPS Currency
- USD
- Contract Type
- SPOT
- ISIN
- US74276L1052
- Asset ID
- equity_e65c5513-7215-53aa-b62b-82394d2ae179
Ownership
Shares Outstanding
Latest: 56.5M | Max: 56.5M | Min: 35.1M
Latest reported ownership snapshot
As of Oct 1, 2026Float Shares
98.76%
55.8M latest reported shares
Insider Ownership
3.48%
Latest reported insider stake
Short Float
0.13%
Latest reported short interest / float
Top Holders
Source tablesView ownership tables
Shares Outstanding
Annual reported shares outstanding; up to 10 reporting dates.
Scroll the table to see every column.
| Reporting date | Shares outstanding |
|---|---|
| 2020-01-01 | 35,138,000 |
| 2021-01-01 | 43,540,000 |
| 2022-01-01 | 44,770,000 |
| 2023-01-01 | 50,589,000 |
| 2024-01-01 | 53,838,000 |
| 2025-01-01 | 56,071,000 |
| 2026-01-01 | 56,511,000 |
Top Holders
Available reported ownership records.
Scroll the table to see every column.
| Holder | Shares | Ownership | Reported date |
|---|---|---|---|
| BlackRock Inc | 4,362,002 | 7.62% | 2026-03-31 |
| T. Rowe Price Investment Management,Inc. | 3,273,794 | 5.72% | 2026-03-31 |
| BNP Paribas Investment Partners SA | 3,089,378 | 5.39% | 2026-03-31 |
| Vanguard Portfolio Management, LLC | 2,421,362 | 4.23% | 2026-03-31 |
| Vanguard Capital Management, LLC | 2,399,067 | 4.19% | 2026-03-31 |
| Chicago Capital LLC | 2,073,237 | 3.62% | 2026-06-30 |
| Mackenzie Investments | 1,720,738 | 3% | 2026-03-31 |
| Vanguard MStar Total Stk Mkt Idx Invest | 1,708,164 | 2.98% | 2026-08-31 |
| State Street Corp | 1,529,631 | 2.67% | 2026-03-31 |
| FMR Inc | 1,461,904 | 2.55% | 2026-03-31 |
| iShares Russell 2000 ETF | 1,436,778 | 2.51% | 2026-08-31 |
| Geode Capital Management, LLC | 1,363,500 | 2.38% | 2026-03-31 |
| T. Rowe Price Small-Cap Stock | 1,317,040 | 2.3% | 2026-07-31 |
| Wellington Management Company LLP | 1,274,004 | 2.22% | 2026-06-30 |
| Federated Hermes Inc | 1,253,420 | 2.19% | 2026-06-30 |
Earnings, Profitability & Valuation
Earnings, Profitability & Valuation
Earnings & Revenue
Earnings and Revenue Trajectory
AI Review
The financial results show a growing medical technology business emerging from a painful inventory correction. Revenue expanded to $308 million in fiscal 2025 and reached $94.5 million in the second quarter of 2026, though annual growth slowed from prior hypergrowth levels. This slowdown happened because hospitals stopped buying excess supplies in bulk and began using up their existing closet inventories. Beneath the messy headline numbers, actual surgical procedures grew 21% in mid-2026. Handpiece sales have fully realigned with real surgeries. While trailing net losses remain significant at $110 million due to clinical trial and sales costs, closing the gap between shipments and surgeries provides a clear path toward financial breakeven.
The financial results show a growing medical technology business emerging from a painful inventory correction. Revenue expanded to $308 million in fiscal 2025 and reached $94.5 million in the second quarter of 2026, though annual growth slowed from prior hypergrowth levels. This slowdown happened because hospitals stopped buying excess supplies in bulk and began using up their existing closet inventories. Beneath the messy headline numbers, actual surgical procedures grew 21% in mid-2026. Handpiece sales have fully realigned with real surgeries. While trailing net losses remain significant at $110 million due to clinical trial and sales costs, closing the gap between shipments and surgeries provides a clear path toward financial breakeven.
Revenue, Net Income, and Free Cash Flow
Latest: USD 308.1M | Max: USD 308.1M | Min: USD -133.2M
Valuation
P/E Ratio (TTM)iPublished valuation snapshots use the earnings basis recorded with each observation. Source tables retain that basis.
Latest: --
No history available.
Profitability & Margins
Margins and Operating Efficiency
AI Review
Gross profit margins tell a positive operational story, climbing from 52.2% in 2023 to 63.7% in 2025 and reaching 66% in mid-2026. This steady expansion reflects strong pricing for single-use surgical handpieces at $3,550 and higher selling prices for next-generation robotic consoles, although a $2.9 million tariff refund provided temporary support. In contrast, operating profit margins remain deeply negative at roughly minus 29% due to extensive sales teams and clinical trial spending. As recurring, high-margin handpiece sales become a larger share of total revenue, fixed corporate overhead will be spread over more cases, paving the way for operating profits as annual surgeries continue to scale.
Gross profit margins tell a positive operational story, climbing from 52.2% in 2023 to 63.7% in 2025 and reaching 66% in mid-2026. This steady expansion reflects strong pricing for single-use surgical handpieces at $3,550 and higher selling prices for next-generation robotic consoles, although a $2.9 million tariff refund provided temporary support. In contrast, operating profit margins remain deeply negative at roughly minus 29% due to extensive sales teams and clinical trial spending. As recurring, high-margin handpiece sales become a larger share of total revenue, fixed corporate overhead will be spread over more cases, paving the way for operating profits as annual surgeries continue to scale.
Profitability Margins
Latest: 63.7% | Max: 63.7% | Min: <-100.0%
Latest Profitability Ratios as of 2025-12-31
Gross Margin
63.7%
Gross profit / revenue
Operating Margin
-33.7%
Operating income / revenue
Net Margin
-31.0%
Net income / revenue
FCF Margin
-18.9%
Free cash flow / revenue
Source tablesView earnings, profitability & valuation tables
Revenue, Net Income, and Free Cash Flow
Annual reported results, using the source statement's recorded USD conversion. Up to 10 reporting periods; missing values are not estimated.
Scroll the table to see every column.
| Period end | Revenue (USD) | Net income (USD) | Free cash flow (USD) |
|---|---|---|---|
| 2019-12-31 | 6,169,000 | -41,975,000 | -51,429,000 |
| 2020-12-31 | 7,717,000 | -53,019,000 | -48,576,000 |
| 2021-12-31 | 34,473,000 | -59,853,000 | -57,926,000 |
| 2022-12-31 | 75,014,000 | -87,154,000 | -83,035,000 |
| 2023-12-31 | 136,191,000 | -105,897,000 | -133,209,000 |
| 2024-12-31 | 224,498,000 | -91,413,000 | -103,622,000 |
| 2025-12-31 | 308,054,000 | -95,572,000 | -58,341,000 |
Published P/E Ratio
Published valuation snapshots retain each observation's earnings basis.
No reported records are available in this preview.
Profitability Margins
Matching annual reporting dates. Values are percentages.
Scroll the table to see every column.
| Period end | Gross margin (%) | Operating margin (%) | Net margin (%) | Free cash flow margin (%) |
|---|---|---|---|---|
| 2019-12-31 | -30.56 | -705.95 | -680.42 | -833.67 |
| 2020-12-31 | -16.26 | -619.44 | -687.04 | -629.47 |
| 2021-12-31 | 46.02 | -157.12 | -173.62 | -168.03 |
| 2022-12-31 | 49.44 | -107.61 | -116.18 | -110.69 |
| 2023-12-31 | 52.17 | -80.16 | -77.76 | -97.81 |
| 2024-12-31 | 61.07 | -43.04 | -40.72 | -46.16 |
| 2025-12-31 | 63.7 | -33.71 | -31.02 | -18.94 |
Public data excerpt created by iPulse AI and published by Future Edge Group FZE. Source: eodhd. Snapshot retrieved 2026-09-29.
Use is subject to the iPulse AI Terms of Service and applicable source rights. Missing inputs are not estimated. Full access includes the remaining records, research and interactive tools.
Complete Research Workspace
Unlock the complete Profile & Fundamentals
Sign in to verify your access, or upgrade to the Base plan to open the complete profile & fundamentals and available source data.